Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSEMKT:RNN
- CUSIP: N/A
- Web: N/A
- Market Cap: $100.42 million
- Outstanding Shares: 25,422,000
- 50 Day Moving Avg: $1.93
- 200 Day Moving Avg: $0.67
- 52 Week Range: $0.38 - $7.10
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.20
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.05 per share
- Price / Book: 79.00
- Average Volume: 5.87 million shs.
- Beta: 0.14
- Short Ratio: 2.4
Frequently Asked Questions for Rexahn Pharmaceuticals (NYSEMKT:RNN)
What is Rexahn Pharmaceuticals' stock symbol?
Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "RNN."
How were Rexahn Pharmaceuticals' earnings last quarter?
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) issued its quarterly earnings data on Monday, August, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.
Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?
3 brokerages have issued twelve-month price objectives for Rexahn Pharmaceuticals' shares. Their forecasts range from $2.00 to $19.50. On average, they anticipate Rexahn Pharmaceuticals' share price to reach $8.17 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.
Who are some of Rexahn Pharmaceuticals' key competitors?
Some companies that are related to Rexahn Pharmaceuticals include Corium International (CORI), Osiris Therapeutics (OSIR), Viralytics Ltd Spon (VRACY), Stemline Therapeutics (STML), Fortress Biotech (FBIO), ConforMIS (CFMS), Arbutus Biopharma Corp (ABUS), Pieris Pharmaceuticals (PIRS), Madrigal Pharmaceuticals (MDGL), Enzymotec Ltd (ENZY), Clearside Biomedical (CLSD), Oxford Biomedica (OXBDF), Neos Therapeutics (NEOS), Kura Oncology (KURA), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Genesis Healthcare (GEN) and Pharming Group (PHGUF).
Who owns Rexahn Pharmaceuticals stock?
Rexahn Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (22.65%), Vanguard Group Inc. (20.54%), Geode Capital Management LLC (5.08%) and Hudson Valley Investment Advisors Inc. ADV (0.08%). View Institutional Ownership Trends for Rexahn Pharmaceuticals.
Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?
How do I buy Rexahn Pharmaceuticals stock?
Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Rexahn Pharmaceuticals stock cost?
One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $3.95.
Earnings History for Rexahn Pharmaceuticals (NYSEMKT:RNN)Earnings History by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS
Dividend History for Rexahn Pharmaceuticals (NYSEMKT:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Rexahn Pharmaceuticals (NYSEMKT:RNN)Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/10/2017||Chang Ho Ahn||Director||Sell||250,000||$0.70||$175,000.00|| |
|1/12/2015||Chang Ho Ahn||Director||Sell||314,656||$0.91||$286,336.96|| |
|1/12/2015||Tae Heum Jeong||CFO||Sell||317,272||$0.91||$288,717.52|| |
|6/12/2014||Chang Ho Ahn||Director||Sell||136,193||$0.99||$134,831.07|| |
|9/9/2013||Tae Heum Jeong||CFO||Sell||71,139||$0.46||$32,723.94|| |
Headline Trends for Rexahn Pharmaceuticals (NYSEMKT:RNN)
Latest Headlines for Rexahn Pharmaceuticals (NYSEMKT:RNN)